Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Evofem Biosciences, Inc. (EVFM)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 93.3% | 23.7% | 212.2% | 26.4% | 21.3% | 25.1% | 49.2% | 55.8% |
| Gross profit | 6.7% | 76.3% | -112.2% | 73.6% | 78.7% | 74.9% | 50.8% | 44.2% |
| Sales and marketing | 89.4% | 66.3% | 3867.4% | 187.5% | 203.8% | 298.9% | 698.1% | 1779.7% |
| Research and development | 16.4% | 9.3% | 933.7% | 81.7% | 128.3% | 244.4% | 242.5% | 508.2% |
| General and administrative | 199.4% | 62.3% | 1745.3% | 98.3% | 151.2% | 212.1% | 158.3% | 289.5% |
| EBITDA | -291.4% | -57.4% | -6520.4% | -290.0% | -400.5% | -674.3% | -1040.1% | -2517.6% |
| Depreciation | 7.0% | 4.2% | 138.1% | 3.9% | 4.1% | 6.2% | 8.0% | 15.7% |
| EBIT | -298.5% | -61.6% | -6658.6% | -293.9% | -404.7% | -680.5% | -1048.1% | -2533.2% |
| Pre-tax income | -348.0% | -40.5% | -4601.1% | 1405.1% | -2087.5% | -750.1% | -1443.9% | -4326.0% |
| Income taxes | 0.1% | 0.1% | 4.4% | 0.2% | 0.3% | 0.1% | 0.2% | 0.0% |
| Net income | -348.2% | -40.5% | -6342.0% | 1404.9% | -2056.2% | -752.0% | -1473.4% | -4326.0% |
|